Effect of biologics targeting IL-23/IL-17 axis on subclinical atherosclerosis: Results of a pilot study.

Effect of biologics targeting IL-23/IL-17 axis on subclinical atherosclerosis: Results of a pilot study.:

Related Articles

Effect of biologics targeting IL-23/IL-17 axis on subclinical atherosclerosis: Results of a pilot study.

Clin Exp Dermatol. 2020 Jan 21;:

Authors: Marovt M, Marko PB, Pirnat M, Ekart R

Abstract

BACKGROUND: Psoriasis is associated with an increased risk of developing atherosclerotic vascular disease. The hypothesis that treatment of skin inflammation may decrease the risk of developing atherosclerosis and consequently, cardiovascular disease, is currently a focus of significant attention.

AIM: To assess the effect of biologics targeting IL-23/IL-17 axis on selected subclinical atherosclerosis parameters in patients with psoriatic disease.

METHODS: In a series of patients with moderate to severe psoriasis, who were eligible for biologic therapy, pulse wave velocity (PWV), and intima-media thickness (IMT), were determined, before therapy and after 6-month treatment (ustekinumab, secukinumab, ixekizumab).

RESULTS: After 6 months of treatment, a remarkable clinical improvement of skin lesions was observed in all patients. No significant changes of IMT values were observed before therapy (0.54 ± 0.9 mm) and after six months (0.53 ± 0.9 mm) (p = .737). No significant changes of PWV values were observed before therapy (8.59 ± 1.96 mm) and after six months (8.89 ± 2.02 mm) (p = .163).

CONCLUSIONS: Systemic treatment of patients with a psoriatic disease with biologics targeting IL-23/IL-17 axis has a possibly neutral effect on atherosclerosis. Additional studies are needed to assess the impact of newer biologic treatments on atherosclerosis.

PMID: 31961453 [PubMed - as supplied by publisher]